$INTI
Inhibitor Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000149315224018805 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $345.4K $539.5K $428.3K
YoY Change -32.08% 25.94% 358.11%
% of Gross Profit
Research & Development $239.8K $235.4K $201.4K
YoY Change 2.47% 16.86%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $585.1K $774.8K $629.7K
YoY Change -21.19% 23.04% 573.5%
Operating Profit -$585.1K -$774.8K -$629.7K
YoY Change -21.19% 23.04% 573.5%
Interest Expense $83.46K $90.11K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$501.7K -$684.7K -$539.6K
YoY Change -23.35% 26.89% 445.55%
Income Tax
% Of Pretax Income
Net Earnings -$501.7K -$684.7K -$539.6K
YoY Change -23.35% 26.89% 445.54%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 172.3M shares 172.0M shares 171.8M shares
Diluted Shares Outstanding 172.3M shares 172.1M shares 171.8M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.099M $7.682M $10.78M
YoY Change -29.72% -28.76% 29490.94%
Cash & Equivalents $7.100M $7.700M $10.78M
Short-Term Investments
Other Short-Term Assets $74.63K $112.4K $52.25K
YoY Change 28.65% 115.12% 111.45%
Inventory
Prepaid Expenses $52.25K
Receivables
Other Receivables
Total Short-Term Assets $7.173M $7.794M $10.84M
YoY Change -29.38% -28.07% 17621.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $7.173M $7.794M $10.84M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $7.173M $7.794M $10.84M
YoY Change -29.38% -28.07% 17621.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.80K $111.9K $5.007K
YoY Change 60.03% 2135.19% -98.44%
Accrued Expenses $16.72K $43.93K $73.44K
YoY Change -47.91% -40.17% 260.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.53K $155.9K $78.44K
YoY Change -19.0% 98.68% -90.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.53K $155.9K $78.44K
Total Long-Term Liabilities $3.000M $3.000M $3.000M
Total Liabilities $3.036M $3.156M $3.078M
YoY Change -0.27% 2.51% -19.63%
SHAREHOLDERS EQUITY
Retained Earnings -$49.97M -$49.46M -$46.29M
YoY Change 6.43% 6.85%
Common Stock $17.23K $17.23K $54.05M
YoY Change -99.97% -99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.138M $4.638M $7.757M
YoY Change
Total Liabilities & Shareholders Equity $7.173M $7.794M $10.84M
YoY Change -29.38% -28.07% 17621.93%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$501.7K -$684.7K -$539.6K
YoY Change -23.35% 26.89% 445.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$583.1K -$1.158M -$757.3K
YoY Change -14.58% 52.93% 1613.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -$411.0K
YoY Change -922.0%
NET CHANGE
Cash From Operating Activities -583.1K -$1.158M -$757.3K
Cash From Investing Activities
Cash From Financing Activities 0.000 -$411.0K
Net Change In Cash -583.1K -$1.158M -$1.168M
YoY Change -14.58% -0.87% -20208.14%
FREE CASH FLOW
Cash From Operating Activities -$583.1K -$1.158M -$757.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
235359 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
201398 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
539458 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
428326 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
774817 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
629724 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-774817 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-629724 usd
CY2024Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
90106 usd
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
90128 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-684711 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172079589 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172079589 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171793134 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171793134 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5283991 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
21000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18090 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-684711 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4638370 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-684711 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39090 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3156 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
28348 usd
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-509314 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-189339 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1158091 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-757283 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
411000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1158091 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1168283 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8839912 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11951224 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7681821 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10782941 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7700000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zeuv69h5sDWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zywsJVYldB0j">Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
270000 shares
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.08
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.07
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
20000.00 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433 pure
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2986 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
40000.00 usd

Files In Submission

Name View Source Status
0001493152-24-018805-index-headers.html Edgar Link pending
0001493152-24-018805-index.html Edgar Link pending
0001493152-24-018805.txt Edgar Link pending
0001493152-24-018805-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inti-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
inti-20240331_cal.xml Edgar Link unprocessable
inti-20240331_def.xml Edgar Link unprocessable
inti-20240331_lab.xml Edgar Link unprocessable
inti-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed